There are some large studies underway that are being funded by the NIH (first link below). It appears to me that no results for the NIH ivermectin trial have been posted yet (second link below).
Oxford had a large ivermectin trial underway but it was halted due to supply issues (third link below). As you can see, Merck has stated "the probability of ivermectin providing a potentially safe and efficacious treatment option for SARS-CoV-2 infection is low."
Despite the lack of solid evidence ivermectin is effective, many doctors are prescribing ivermectin, and insurance companies are picking a big chunk of the cost (fourth link below). Just because ivermectin is not FDA approved for treating COVID doesn't mean doctors can't prescribe it.
It's somewhat puzzling why so many people are apparently upset that the FDA has not approved ivermectin for treating COVID. I can't prove it, but my impression is that a lot of the people clamoring for FDA approval of ivermectin are the same people who are skeptical of the FDA approval of the COVID vaccines and Paxlovid.
>>>Large Clinical Trial to Study Repurposed Drugs to Treat COVID-19 Symptoms
April 19, 2021
Using an ACTIV master protocol, the trial will focus on potential interventions for mild-to-moderate illness
The National Institutes of Health will fund a large, randomized, placebo controlled Phase 3 clinical trial to test several existing prescription and over-the-counter medications for people to self-administer to treat symptoms of COVID-19. Part of the Accelerating COVID 19 Therapeutic Interventions and Vaccines (ACTIV) public–private partnership, the ACTIV-6 trial aims to provide evidence-based treatment options for the majority of adult patients with COVID-19 who have mild-to-moderate symptoms and are not sick enough to be hospitalized. NIH will provide an initial investment of $155 million in funding for the trial. . . . Enrollment is open to test the safety and effectiveness of ivermectin, fluvoxamine and fluticasone in treating mild to moderate COVID-19 symptoms at home. Agent prioritization is ongoing, and additional study arms may open. For the latest information on the drugs being studied, visit the ACTIV website.<<<
CTSA Program implements a large clinical trial for mild to moderate COVID-19 to test several existing drugs, including ivermectin, fluvoxamine and fluticasone.
ncats.nih.gov
clinicaltrials.gov
>>>The ivermectin arm of the U.K.'s PRINCIPLE trial is "currently paused due to temporary supply issues," according to the trial's website.
The website does not offer any details on what caused the ivermectin supply difficulties in PRINCIPLE, which is investigating possible treatments for COVID-19 and being led by the University of Oxford in England. . . .Ivermectin manufacturer Merck did not directly comment on the supply issues affecting PRINCIPLE. However, as part of a longer statement on the drug provided to MedPage Today via email, the company said that it has "concluded that the probability of ivermectin providing a potentially safe and efficacious treatment option for SARS-CoV-2 infection is low and have prioritized internal efforts towards the development of alternate candidates that provide a higher probability of success for the treatment of COVID-19."
"If clinical data emerge providing definitive evidence for a positive benefit-risk assessment of the use of ivermectin in COVID-19, we stand ready to provide our expertise and resources as needed," Merck added.<<<
Trial website cites supply issues
www.medpagetoday.com
>>>“Insurers usually don’t cover ineffective treatments, or at least make patients pay for most of the cost,” said Kao-Ping Chua, M.D., Ph.D., the health care researcher from U-M who led the study. “Our study suggests that they are treating ivermectin prescriptions for COVID-19 differently. In doing so, they are reducing barriers to an ineffective drug that some are using as a substitute for COVID-19 vaccination or evidence-based treatments.” . . . “To be clear, clinicians may still prescribe ivermectin for COVID-19 and patients can choose to pay for these prescriptions themselves. Our point is simply that insurers shouldn’t cover these prescriptions unless ivermectin proves to be an effective COVID-19 treatment,” said Chua, a pediatrician at Michigan Medicine’s C.S. Mott Children’s Hospital and the Susan B. Meister Child Health Evaluation and Research Center. . . . The authors then estimated that all but 3,600 of the 88,000 ivermectin prescriptions filled in the week of August 13, 2021 were for COVID-19. Assuming that the study’s results generalized to these prescriptions, the authors estimated that private and Medicare plans paid $2.4 million for the prescriptions in this week alone.<<<
Study shows health plans paid most of the cost of ivermectin, despite drug’s lack of effect on COVID-19.
labblog.uofmhealth.org